Sinopharm Group Co. Ltd.
SHTDF | OTC
$2.01
-$0.07 (-3.38%)
At close: Oct 30, 2026, 12:40 PM ET
$2.01
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 4:00 PM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q4 2025 Dec 31, 2025 | Q2 2025 Jun 30, 2025 | Q4 2024 Dec 31, 2024 | Q2 2024 Jun 30, 2024 | Q4 2023 Dec 31, 2023 | Q2 2023 Jun 30, 2023 | Q4 2022 Dec 31, 2022 | Q2 2022 Jun 30, 2022 | Q4 2021 Dec 31, 2021 | Q2 2021 Jun 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 278.9B | 289.12B | 286.04B | 289.78B | 294.73B | 295.62B | 300.95B | 145.77B | 261.47B | 271.93B | 249.12B |
Cost of Revenue | 260.31B | 267.8B | 265.27B | 267.47B | 272.78B | 270.38B | 277.68B | 119.99B | 239.81B | 248.47B | 228.53B |
Gross Profit | 18.59B | 21.33B | 20.78B | 22.31B | 21.94B | 25.24B | 23.27B | 25.78B | 21.66B | 23.46B | 20.59B |
Operating Income | 8.17B | 8.59B | 7.14B | 7.97B | 8.22B | 10.38B | 9.83B | 13.25B | 9.51B | 11.91B | 9.07B |
Interest Income | 160.78M | 241.3M | 273.75M | 246.82M | 422.02M | -778.48M | 1.3B | 330.33M | 1.48B | 1.68B | 1.48B |
Pretax Income | 6.85B | 7.59B | 7.2B | 6.4B | 7.6B | 10.65B | 8.87B | 5.97B | 8B | 9.29B | 7.72B |
Net Income | 3.36B | 3.69B | 3.46B | 3.35B | 3.7B | 4.95B | 4.1B | 4.83B | 3.69B | 4.18B | 3.58B |
Selling & General & Admin | 10.42B | 11.99B | 12.51B | 13.19B | 12.38B | 13.09B | 13.69B | 7.81B | 12.38B | 11.9B | 11.76B |
Research & Development | n/a | n/a | 123.36M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | -1.47M | 743.81M | 1.01B | 1.16B | 1.34B | 2.12B | 426.37K | 129.94B | -11.86M | -15.5M | 211.19K |
Operating Expenses | 10.42B | 12.73B | 13.63B | 14.35B | 13.72B | 15.2B | 13.1B | 137.75B | 12.18B | 12.5B | 11.39B |
Interest Expense | 958.33M | 1.22B | 457.11M | 1.14B | 965.5M | n/a | n/a | 1.27B | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | 8.34B | 7.84B | 8.68B | 8.48B | 9.04B | 8.43B | 4.8B | 7.78B | 7.83B | 7.61B |
Cost & Expenses | 270.73B | 280.53B | 278.9B | 281.81B | 286.51B | 284.12B | 290.78B | 137.75B | 251.99B | 260.97B | 239.93B |
Income Tax Expense | 1.74B | 2.09B | 1.87B | 1.88B | 1.7B | 2.53B | 1.97B | 1.44B | 1.78B | 2.25B | 1.69B |
Shares Outstanding (Basic) | 3.12B | 3.12B | 3.12B | 3.11B | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B |
Shares Outstanding (Diluted) | 3.12B | 3.12B | 3.12B | 3.11B | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B |
EPS (Basic) | 1.07 | 1.18 | 1.11 | 1.07 | 1.19 | 1.59 | 1.32 | 1.55 | 1.19 | 1.34 | 1.15 |
EPS (Diluted) | 1.07 | 1.18 | 1.11 | 1.07 | 1.19 | 1.59 | 1.32 | 1.55 | 1.19 | 1.34 | 1.15 |
EBITDA | 10.13B | 10.44B | 9.93B | 10.65B | 9.53B | 13.5B | 10.91B | 9.67B | 10.55B | 12.84B | 10.06B |
EBIT | 8.17B | 9.52B | 7.7B | 9.44B | 8.38B | 12.49B | 9.83B | 7.24B | 9.51B | 11.91B | 9.07B |
Depreciation & Amortization | 1.97B | 915.5M | 2.23B | 1.21B | 1.15B | 1.01B | 1.07B | 2.43B | 1.04B | 927.22M | 984.69M |
Add to Watchlist
Select watchlists to add or remove SHTDF